Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and autoantibody-driven diseases. Headquartered in Wellesley Hills, Massachusetts, the company primarily develops monoclonal antibody therapeutics designed to modulate B-cell biology. The company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells and reduce pathogenic autoantibodies. Budoprutug is being advanced across multiple indications, including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. Additionally, Climb Bio is developing CLYM116, a preclinical-stage anti-APRIL monoclonal antibody targeting IgA nephropathy and other B-cell mediated diseases. Formerly known as Eliem Therapeutics, the company rebranded to Climb Bio in October 2024 to reflect its strategic shift toward immunology.
